podophyllotoxin has been researched along with B-Cell Lymphoma in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (23.08) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellò, M; Benevolo, G; Bisi, G; Boccomini, C; Botto, B; Castellino, A; Chiappella, A; Ciochetto, C; Freilone, R; Nicolosi, M; Orsucci, L; Passera, R; Pecoraro, C; Pregno, P; Vitolo, U | 1 |
| Arcani, R; Colle, J; Costello, RT; Fanciullino, R; Farnault, L; Ivanov, V; Jourde-Chiche, N; Mercier, C; Pourroy, B; Roche, P; Venton, G | 1 |
| Belada, D; Berková, A; Bolomská, I; Burešová, L; Campr, V; Klener, P; Kozák, T; Kubáčková, K; Matuška, M; Pirnos, J; Přibylová, J; Pytlík, R; Sýkorová, A; Trněný, M; Vášová, I | 1 |
| Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M | 1 |
| Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H | 1 |
| Buerger, T; Gebauer, T; Halloul, Z; Meyer, F | 1 |
| Boruczkowski, D; Choma, M; Chybicka, A; Drabko, K; Gorczyńska, E; Kałwak, K; Kowalczyk, JR; Pieczonka, A; Toporski, J; Turkiewicz, D; Wachowiak, J; Wójcik, B; Zaucha-Prazmo, A | 1 |
| Antonenas, V; Bradstock, K; Collins, D; Crowther, H; Gottlieb, D; Kerridge, I; McGurgan, M | 1 |
| Gisselbrecht, C; Hagberg, H | 1 |
| Huijgens, PC; Keijzer, A; van de Loosdrecht, AA | 1 |
| Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL | 1 |
| Azaceta, G; Palomera, L; Soria, J; Varo, MJ | 1 |
| Amigo, ML; del Cañizo, MC; Gonzalez, MB; Gutiérrez, N; Hernández, JM; Mateos, MV; San Miguel, JF | 1 |
4 trial(s) available for podophyllotoxin and B-Cell Lymphoma
| Article | Year |
|---|---|
Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Italy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Invasiveness; Podophyllotoxin; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2018 |
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Combined Modality Therapy; Cytarabine; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Radioimmunotherapy; Radiotherapy Dosage; Salvage Therapy; Transplantation, Autologous | 2009 |
(90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Rituximab; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Young Adult | 2011 |
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cisplatin; Combined Modality Therapy; Cytarabine; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Podophyllotoxin; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
9 other study(ies) available for podophyllotoxin and B-Cell Lymphoma
| Article | Year |
|---|---|
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Renal Insufficiency; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning | 2019 |
Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial.
Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Consolidation Chemotherapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Humans; Induction Chemotherapy; Lymphoma, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Podophyllotoxin; Prednisone; Prognosis; Rituximab; Treatment Outcome; Vincristine; Young Adult | 2015 |
Unusual implantation site of a port-a-cath system via the right femoral vein.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Catheterization, Central Venous; Catheters, Indwelling; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, B-Cell; Mediastinal Neoplasms; Melphalan; Podophyllotoxin; Radiography; Thrombosis; Transplantation, Autologous | 2002 |
[Autologous stem-cell transplantations in children with non-Hodgkin lymphomas].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Melphalan; Podophyllotoxin; Poland; Retrospective Studies; Survival Analysis; Time Factors; Transplantation, Autologous; Treatment Outcome | 2004 |
Successful autologous peripheral blood stem cell harvest and transplant in a patient with cold agglutinins.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryoglobulins; Cytarabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Transplantation, Autologous | 2006 |
Palifermin and palmar-plantar erythrodysesthesia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Drug Hypersensitivity; Female; Fibroblast Growth Factor 7; Foot Dermatoses; Hand Dermatoses; Humans; Lymphoma, B-Cell; Melphalan; Middle Aged; Mitogens; Podophyllotoxin | 2007 |
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine | 1995 |
[Intensive treatment of T-cell-rich B lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Lymphoma, B-Cell; Male; Melphalan; Podophyllotoxin; Prednisone; Remission Induction; T-Lymphocyte Subsets; Vincristine | 1998 |
Clonal myelodysplastic cells present in apheresis product before transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Chromosome Aberrations; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 7; Cyclophosphamide; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma, B-Cell; Lymphoma, Follicular; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies | 1998 |